Search - tctmd.com

Displaying 81 - 100 of 1780

Sort: Relevancy | Date

Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI

News Conference News EuroPCR 2025

Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI

Michael O'Riordan

May 21, 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

Higher CVD Risk in Children as Young as 10 Who Have Central Adiposity

News Conference News European Congress on Obesity 2025

Higher CVD Risk in Children as Young as 10 Who Have Central Adiposity

Michael O'Riordan

May 16, 2025

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

News Conference News European Congress on Obesity 2025

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

Michael O'Riordan

May 14, 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

News Conference News European Congress on Obesity 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Michael O'Riordan

May 13, 2025

Tirzepatide Tops Semaglutide for Weight Loss SURMOUNT-5

News Conference News European Congress on Obesity 2025

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Michael O'Riordan

May 12, 2025

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

HDL Cholesterol Levels May Sway Statin Decisions in Primary Prevention

News Daily News

HDL Cholesterol Levels May Sway Statin Decisions in Primary Prevention

Michael O'Riordan

May 02, 2025

Donor Hearts Fare Better With Novel Method After Circulatory Death

News Daily News

Donor Hearts Fare Better With Novel Method After Circulatory Death

Michael O'Riordan

May 01, 2025

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

News Daily News

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Michael O'Riordan

May 01, 2025

Medicaid Patients with Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

Weekend Warriors Also See Mortality Benefits With Exercise

News Daily News

Weekend Warriors Also See Mortality Benefits With Exercise

Michael O'Riordan

April 10, 2025

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

News Daily News

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

Michael O'Riordan

April 09, 2025

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

News Conference News ACC 2025

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

Michael O'Riordan

April 08, 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

News Conference News ACC 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

Michael O'Riordan

April 04, 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.